1. Introduction {#sec1}
===============

Antimicrobial resistance (AMR) is one of the greatest threats to our society ([@bib29]). Among other sources, humans may acquire AMR bacterial infections or AMR-encoding genes through the consumption of contaminated food, including fish and shellfish ([@bib6], [@bib22]). In recent years shrimp farming has rapidly increased, reaching a global production of 3.2 million metric tons in 2017, much of it taking place in Asia ([@bib4]). This increase is happening in a context of rapid globalization of markets, as well as the threat of climate change ([@bib20]). Antimicrobials are widely used in shrimp and aquaculture production, both to treat and prevent diseases ([@bib15]). Contamination of aquaculture food products with antimicrobial residues represents a potential health hazard to the consumer due to food poisoning, the development of allergy problems, changes of the intestinal flora, as well as the emergence and subsequent spread of antimicrobial resistance ([@bib30]).

Non-typhoidal *Salmonella* (NTS) and certain *Vibrio* spp. are major microbiological hazards associated with shrimp and seafood consumption ([@bib5], [@bib41]). *Vibrio parahaemolyticus* is the leading cause of seafood-borne bacterial gastroenteritis in the world. Both its thermostable direct hemolysin (*tdh*) and tdh-related hemolysin (*trh*) are considered major virulence factors of this micro-organism ([@bib35]). In the late 1990s', *V. parahaemolyticus* was implicated in a large outbreak of enteric disease in central Vietnam, with 523 cases reported ([@bib9]).

NTS is a major cause of gastroenteritis worldwide ([@bib24]). In Vietnam, NTS is recognised as a major cause of pediatric diarrhoea ([@bib39]). There is also evidence of an increase in the incidence of severe invasive infections in hospitalised patients associated due to this organism ([@bib19], [@bib27]).

The Vietnamese shrimp industry has experienced a considerably expansion over recent years, with most of its production being aimed the export market (mostly to the USA, Europe and Japan). In 2017, shrimp exports made up about half of the total Vietnam seafood exports, with sales worth 3.8 billion US\$ ([@bib16]).

Shrimp exports are regularly screened for their microbiological safety by the companies themselves. However, little is known about the microbiological safety of shrimps available for domestic consumption. Therefore, the aims of this study were: (1) to investigate major foodborne hazards associated with shrimps from local retail sites in Ho Chi Minh City (HCMC), Vietnam, such as antimicrobial residues, NTS and *Vibrio* spp.; and (2) to characterise the AMR profile of these organisms, including the presence of Extended Spectrum Beta-Lactamases (ESBL) and colistin resistance. In addition we investigated the relationship between the presence of AMR in the two bacterial species and antimicrobial residues in the same batches, which to our knowledge has not been previously investigated.

2. Methods {#sec2}
==========

2.1. Sample collection and identification {#sec2.1}
-----------------------------------------

Batches of shrimps (250--300 g each) were purchased from 40 different retail sites located in 10 districts of HCMC (Vietnam) from March to June 2018. In order to maximize the diversity of sources, from each district three street markets and one supermarket were selected. From each retail site, one batch of live or dead shrimps (chilled, not frozen) was purchased. Shrimps were collected into a clean plastic bag, and were transported to the laboratory within 2 h in an ice-containing box. Five representative specimens *per* batch were weighted using precision scales. Shrimp species were identified based on their morphological features. Using a pair of sterile scissors, the heads, legs and exoskeleton were separated from the muscle tissue, and were subsequently pooled (shell mix). Muscle tissue samples were investigated for the presence of antimicrobial residues, and the shell mixes were investigated for NTS and *Vibrio* spp.

2.2. Antimicrobial residue analyses {#sec2.2}
-----------------------------------

Shrimp muscle tissue samples were investigated for antimicrobial residues using a hierarchical approach. Firstly, they were screened using PremiTest (R-Biopharm AG, Germany), an assay based on the inhibition growth of *Bacillus stearothermophilus* spores. Positive or inconclusive result samples were then examined for the presence of macrolides, amphenicols, tetracyclines, β-lactams and sulfonamides antimicrobial classes, as well as for the presence of chloramphenicol, streptomycin and gentamicin/neomycin using a Charm II analyzer 7600 (Charm Sciences, USA) ([@bib12]). Samples that tested positive by Charm II were then confirmed for specific antimicrobials within each class by Ultra-High Performance Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS). In addition, PremiTest-positive samples were investigated for quinolones by LC-MS/MS. (See [Table A](#appsec1){ref-type="sec"} with the list of antimicrobials investigated by LC-MS/MS).

2.3. Isolation of NTS and vibrio spp. {#sec2.3}
-------------------------------------

The shrimp shell mixes were investigated for NTS using a modified ISO 6579--1:2017 method. Briefly, from each sample 25 g of homogenized shell mix was pre-enriched in 225 mL buffered peptone water (BPW, Oxoid, UK) at 37 °C for 18 h. A loop of pre-enrichment media was then inoculated on Modified Semi-solid Rappaport-Vassiliadis (MSRV, Oxoid, UK), and incubated at 41.5 °C for 24 h. and positive growth was further inoculated on chromogenic Rambach agar (CHROMagar, France) and incubated at 37 °C for 24 h ([@bib8]). Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) (Bruker, Germany) was used to investigate the species identity of three suspected (pink) isolates from each culture. NTS isolates were further classified as either group B, C, D, E or 'others' according to the Kauffmann-White scheme using relevant poly-O antiserum ([@bib14]). Shrimp shell mixes (25 g) were also investigated for the presence of *Vibrio* spp. using a modification of the ISO/TS 21872--1:2007 method. Briefly, the steps were: (1) 25 g of the shell mix was suspended in 225 mL of alkaline saline peptone water (ASPW) at 41.5 °C for 24 h; (2) a loop of enrichment was cultured on thiosulfate citrate bile and sucrose agar (TCBS, Oxoid, UK) at 37 °C for 24 h. Four suspected *Vibrio* spp. isolates from each sample were confirmed by MALDI-TOF.

2.4. Antimicrobial susceptibility testing {#sec2.4}
-----------------------------------------

All confirmed NTS isolates were tested for their antimicrobial susceptibility against a panel of 34 antimicrobials belonging to 11 classes by Vitek (bioMérieux, Marcy l'Etoile, France) ([@bib23]) (33 antimicrobials), as well as by Etest (BioMérieux, France) (colistin). All *Vibrio* spp. isolates were tested using the disk diffusion method for 12 antimicrobials representative of eight classes (Oxoid, UK). The full list of antimicrobials investigated is displayed in [Tables C4 and C5](#appsec1){ref-type="sec"}. NTS and *Vibrio* spp. isolates were classified as susceptible, intermediate or resistant according to CLSI guidelines (M100-S27 for NTS, M45-A2 for *Vibrio* spp.) ([@bib1], [@bib2]). A strain was defined as 'multidrug resistant' (MDR) if it was fully resistant to antimicrobials belonging to at least three different classes. The potential production of ESBLs was investigated by the 'comparative disk diffusion method', using cefotaxime and ceftazidime disks alone, as well as in combination with clavulanate ([@bib2]). Antimicrobial susceptibility results were sorted according to the WHO list of antimicrobials of human health importance ([@bib3]).

2.5. Determination of serovar identity of NTS {#sec2.5}
---------------------------------------------

NTS isolates were further classified as belonging to either group B, C, D, E or 'others' according to the Kauffmann-White scheme using poly-O antiserum ([@bib14]). From each sample, one isolate representative of each a serogroup-antimicrobial susceptibility testing result pattern was investigated by Multi-Locus Sequence Typing (MLST). The MLST scheme followed is based on seven loci *aro*C, *dna*N, *hem*D, *his*D, *pur*E, *suc*A and *thr*A ([@bib47]).

2.6. Investigation of tdh and trh genes of vibrio spp. by PCR {#sec2.6}
-------------------------------------------------------------

The presence of genes encoding a thermostable direct hemolysin (*tdh*) and a tdh-related hemolysin gene (*trh*) was investigated by PCR in all *Vibrio* spp. isolates ([@bib38]). Positive and negative control isolates were used. The positive control isolates originated from confirmed human cases.

2.7. Investigation of ESBL and plasmid mediated colistin resistance-encoding genes by PCR {#sec2.7}
-----------------------------------------------------------------------------------------

The presence of *bla*~CTX-M(1,\ 2,\ 8,\ 9\ and\ 25)~, *bla*~TEM~, *bla*~SHV~, and *bla*~OXA~ genes (all encoding extended-spectrum *β*-lactamases) was investigated by multiplex PCR ([@bib10]) in all NTS and *Vibrio* spp. isolates that tested positive phenotypically for ESBL. The presence of plasmid-mediated genes (*mcr*-1 to *mcr*-5) among phenotypic colistin-resistant isolates was investigated by multiplex PCR ([@bib36]).

2.8. Statistical analyses {#sec2.8}
-------------------------

We investigated 40 shrimp batches with the aim of determining the prevalence of residues, based on an expected prevalence of 8%, a 95% level of confidence and an 8% relative precision. We expected to obtain 50 NTS isolates from these batches. This sample size (50) allowed determining a prevalence of MDR of ∼27% (based on published data) with a 95% level of confidence and a 9% relative precision. The prevalence of contamination and resistance across variables was compared using chi-square tests. The level of agreement between presence of residues and presence of intermediate (or resistant) isolates in each shrimp batch sample was investigated using the kappa statistic.

3. Results {#sec3}
==========

3.1. Shrimp samples {#sec3.1}
-------------------

The 40 batches investigated included specimens of five shrimp species: white leg shrimp (*Litopenaeus vannamei*) (30) (22.5 g weight; 16.2 ± Standard Deviation (SD) 1.2 cm length), giant tiger shrimp (*Penaeus monodon*) (5) (22.0 g; 15.4 ± SD 1.4 cm), banana shrimp (*Penaeus merguiensis*) (3) (17.3 g, 12.5 ± SD 1.6 cm), greasy-back shrimp (*Metapenaeus ensis)* (1) (11.5 g; 11.5 ± SD 1.4 cm), and giant prawn (*Macrobrachium rosenbergii*) (34.3 g; 16.6 ± SD 1.1 cm). The descriptive data for the samples investigated, and the prevalence of PremiTest, NTS and *Vibrio* spp. sample positivity results are shown in [Table 1](#tbl1){ref-type="table"}.Table 1Description, prevalence of residues, NTS and *Vibrio* spp. among 40 shrimp batches purchased in HCMC.Table 1VariableNo. samplesNo. (%) positivePremiTestNTS (%)*Vibrio* species*V. parahaemolyticusV. navarrensisV. alginolyticusV. cholerae non-O1V. vulnificusV. fluvialisType of retail site* Supermarket105 (50.0%)6 (60.0%)9 (90.0%)7 (70.0%)4 (40%)6 (60.0%)2 (20.0%)0 (0%) Street market304 (13.3%)24 (80.0%)26 (86.7%)17 (56.7%)17 (56.7%)9 (30.0%)7 (23.3%)4 (13.3%)*Shrimp species* White leg shrimp308 (26.7%)22 (73.3%)26 (86.7%)15 (50.0%)16 (53.3%)12 (40.0%)7 (23.3%)4 (13.3%) Giant tiger shrimp51 (20.0%)3 (60.0%)4 (80.0%)5 (100%)2 (40.0%)2 (40.0%)1 (20.0%)0 (0%) Other species50 (0%)5 (100%)5 (100%)4 (80%)3 (60%)1 (20%)1 (20%)0 (0%)*Condition* Alive173 (17.6%)12 (70.6%)16 (94.1%)8 (47.1%)11 (64.7%)4 (23.5%)5 (29.4%)4 (23.5%) Dead236 (26.1%)18 (78.3%)19 (82.6%)16 (69.6%)10 (43.5%)11 (47.8%)4 (17.4%)0 (0%)*Retail price (per kg)* ≤170 k VND[a](#tbl1fna){ref-type="table-fn"}226 (27.3%)14 (63.6%)18 (81.8%)14 (63.6%)12 (54.5%)9 (40.9%)5 (22.7%)1 (4.5%) \>170 k VND183 (16.7%)16 (88.9%)17 (94.4%)10 (55.6%)9 (50%)6 (33.3%)4 (22.2%)3 (16.7%)*Total*409 (22.5%)30 (75.0%)35 (87.5%)24 (60.0%)21 (52.5%)15 (37.5%)9 (22.5%)4 (10.0%)[^1]

3.2. Antimicrobial residues {#sec3.2}
---------------------------

Antimicrobial residues were detected in 9/40 (22.5%) samples by PremiTest. Shrimp samples from supermarkets had a higher prevalence of antimicrobial residues than those purchased in street markets (50% vs. 13.3%) (*χ*^2^ = 3.871, *p* = 0.049). Four of the nine PremiTest-positive samples were positive by Charm II, whereas the remaining five tested negative ([Table 2](#tbl2){ref-type="table"}). Tetracyclines, sulfonamides, and macrolides were detected by Charm II in 7.5%, 2.5%, and 2.5% of samples, respectively. Antimicrobials identified by LC-MS/MS included two tetracycline antimicrobials (tetracycline and oxytetracycline) and two fluoroquinolone antimicrobials (ciprofloxacin and flumequine). The Charm II macrolide-positive sample tested negative for both tylosin and erythromycin by LC-MS/MS. Two samples contained antimicrobial residues above the maximum residue limits (MRL) according to Vietnamese regulations (one contained tetracycline and sulfamethoxazole; another oxytetracycline, and ciprofloxacin). Oxytetracycline and flumequine were also found in two other samples although at concentrations below the MRL (43.7* μ*g/kg and 41.2* μ*g/kg, respectively).Table 2Results of antimicrobial residue testing by Charm II and LC-MS/MS among 9 shrimp samples that tested positive by PremiTest.Table 2Sample IDDescriptionCharm II (antimicrobial class)LC-MS/MS (antimicrobial)Concentration of antimicrobial active ingredient (*μ*g/kg)MRL (*μ*g/kg)1White leg shrimp, deadTetracyclinesTetracycline590.7100SulfonamidesSulfamethoxazole157.6100Flumequine[a](#tbl2fna){ref-type="table-fn"}38.52002White leg shrimp, deadTetracyclinesOxytetracycline122.2100Ciprofloxacin\*30Not allowed3White leg shrimp, deadMacrolidesND----Flumequine[a](#tbl2fna){ref-type="table-fn"}41.22004White leg shrimp, deadTetracyclinesOxytetracycline43.71005White leg shrimp, deadNDND----6White leg shrimp, liveNDND----7White leg shrimp, liveNDND----8White leg shrimp, liveNDND----9Tiger shrimp, deadNDND----[^2]

3.3. Prevalence of contamination with NTS serovars and vibrio spp. {#sec3.3}
------------------------------------------------------------------

A total of 90 NTS isolates were recovered from 30/40 (75%) shrimp batches ([Table 1](#tbl1){ref-type="table"}). The prevalence of NTS among samples purchased in street markets was higher than that from supermarket samples, although this difference was not significant (80% vs. 60%; *χ*^2^ = 0.711; p = 0.399). There was lower probability of recovering NTS from PremiTest-positive samples than from PremiTest-negative samples (5/9 vs. 25/31), although this difference was not significant (Fisher's exact test, p = 0.190). MLST was performed on 62 isolates with a unique serogroup-antimicrobial susceptibility pattern. The remaining 28 isolates were assigned to serovar based on MLST results of isolates recovered from the same sample and with the same serogroup-AST pattern. A total of 28 MLST sequence types (ST) corresponding to 25 NTS serovars were identified. One NTS strain (Group B) could not be assigned to ST, and therefore its serovar identity was not determined ([Table B](#appsec1){ref-type="sec"}). The most prevalent serovars identified were Braenderup (present in 20% samples), Anatum (16.7% samples), Saintpaul (13.3% samples), Rissen and Litchfield (10% samples each). All (100%) samples were positive for *Vibrio* species, yielding 133 isolates. Among six *Vibrio* species, *V. parahaemolyticus* was the most common species (87.5% samples), followed by *V. navarrensis* (60%), *V. alginolyticus* (52.5%), *V. cholerae non-O1* (37.5%), *V. vulnificus* (22.5%) and *V. fluvialis* (10%) ([Table 1](#tbl1){ref-type="table"}).

3.4. Antimicrobial susceptibility among NTSisolates {#sec3.4}
---------------------------------------------------

Among highest priority-critically important antimicrobial classes, the highest prevalence of resistance corresponded to quinolones (nalidixic acid, ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin) (range 14.4--47.8%), followed by 3rd and 4th generation cephalosporins (cefixime, cefotaxime, ceftazidime and ceftriazone) (3.3--7.8%). Among high priority-critically important antimicrobials, resistance was highest against aminoglycosides (16.7% gentamicin and 7.8% tobramycin), monobactams (7.8% aztreonam), and glycylcyclines (3.3% tigecycline) ([Fig. 1](#fig1){ref-type="fig"}, [Table C](#appsec1){ref-type="sec"}). A total of 58.9% isolates were MDR. The highest prevalence of MDR corresponded to Group B isolates (76.2%; 95% CI 58.0--94.4%), followed by Group D (75.0; 95% CI 32.6--100%) and Group C (51.4%; 95% 35.2--67.5%). Seven isolates (7.8%) (from 3 samples) were identified as ESBL-positive. They were identified as serovars Infantis (3), Give (3) and Braenderup (1). The isolates identified as Infantis and Give (three of each, from two different samples) had identical antimicrobial susceptibility profile.Fig. 1Phenotypic resistance of NTS isolates by group. Pale bars indicate the percent of isolates showing intermediate resistance; dark bars indicate percent of isolates with full resistance. 95% binomial confidence intervals have been drawn around the percentage of resistant plus intermediate resistant isolates.Fig. 1

3.5. Antimicrobial resistance of vibrio spp. isolates {#sec3.5}
-----------------------------------------------------

Results of antimicrobial susceptibility testing of 133 of *Vibrio* spp. against 12 antimicrobial drugs are shown in [Fig. 2](#fig2){ref-type="fig"} and in [Table D](#appsec1){ref-type="sec"}. The highest prevalence of resistance corresponded to ampicillin (82.7%), followed by co-trimoxazole (18.8%) and 3rd generation cephalosporins (16.5% cefotaxime; , 8.3% ceftazidime). All (100%) *V. parahemolyticus* and *V. alginolyticus* isolates were fully resistant to ampicillin. The prevalence of resistance against amoxicillin-clavulanic, penems, aminoglycosides, tetracyclines, quinolones and phenicols was \<11.3% in all cases. A total of 18/64 (28.1%) *V. parahaemolyticus* were ESBL producers; however none (0%) of the 69 non-*V. parahaemolyticus* strains were ESBL producers. Overall, 18 of 133 (13.5%) *Vibrio* spp. isolates were MDR, but this percent was 28.1% among *V. parahemolyticus*, and 0% among other *Vibrio* species.Fig. 2Phenotypic resistance of *Vibrio* spp. isolates. Pale bars indicate the percent of isolates showing intermediate resistance; dark bars indicate percent of isolates with full resistance. 95% binomial confidence intervals have been drawn around the percentage of resistant plus intermediate resistant isolates.Fig. 2

3.6. Detection of toxin-encoding genes {#sec3.6}
--------------------------------------

None of the 133 *Vibro* spp. isolates tested positive for either the *tdh* or *trh* genes.

3.7. Detection of ESBL genes in NTS and vibrio spp. isolates {#sec3.7}
------------------------------------------------------------

The phenotypically ESBL-positive serovar Branderup isolate tested negative for all ESBL genes investigated. All three serovar Infantis isolates (from the same sample) were positive for *bla*~CTX-M9~. The three serovar Give isolates tested positive for both *bla*~CTX-M1~ and *bla*~TEM~. Interestingly, all isolates were fully susceptible to cefepime and cefoxitin. A total of 9/18 (50%) ESBL-positive *V. parahaemolyticus* strains were positive for *bla*~CTX-M1~. In addition, one of these isolates tested positive to the *bla*~TEM~ gene.

3.8. Relationship between residues, and AMR in NTS and vibrio spp. isolates {#sec3.8}
---------------------------------------------------------------------------

NTS isolates from shrimp samples that tested positive to PremiTest (n = 15) were resistant to a median of 10 antimicrobials \[IQR 3--13\], whereas NTS isolates from samples testing negative (n = 75) were resistant to 5 antimicrobials \[IQR 0--9\] (Wilcoxon test W = 724.5, p = 0.075). *Vibrio* spp. isolates from PremiTest-positive samples (n = 29) were resistant to a median of 1 \[IQR 1--4\] antimicrobial, compared with 1 \[IQR 1--2\] among *Vibrio* spp. from PremiTest-negative samples (n = 104) (Wilcoxon = 1792; p = 0.093) ([Fig. 3](#fig3){ref-type="fig"}). We found fair agreement between presence of residue (PremiTest) and presence of co-trimoxazole and ciprofloxacin resistant NTS from the same sample (kappa values 0.265 and 0.365; p ≤ 0.016). We also found a fair agreement between presence of a quinolone residue and ciprofloxacin resistance in *Vibrio* spp. isolates from the same sample (kappa = 0.383; p = 0.005). In addition, there was a moderate agreement between samples that contained ESBL-positive *Vibrio* spp. and ESBL-positive NTS isolates (kappa = 0.515, p \< 0.001) ([Table D](#appsec1){ref-type="sec"}). However, in neither of the two samples that contained both phenotypically ESBL-positive NTS and *Vibrio* spp. we could demonstrate the presence of the same genes: in one sample *V. parahaemolyticus* was positive for both *bla*~TEM~ and *bla*~CTX-M1~, whereas no ESBL genes were detected in the NTS isolate; in the other, NTS harboured the *bla*~CTX-M9~, wheras *V. parahaemolyticus* tested negative for all ESBL genes.Fig. 3Number of phenotypic resistances among NTS and *Vibrio* spp. isolates from PremiTest-positive and PremiTest-negative shrimp samples.Fig. 3

4. Discussion {#sec4}
=============

This study evidenced a high prevalence of contamination of shrimp samples with antimicrobial residues (22.5%), NTS (75%), and *Vibrio* spp. (100%). This result is in line with a previous survey of shrimps from local markets in the Red River and Mekong Delta regions of Vietnam (13.0% and 33.3%, respectively) ([@bib32]), but higher than previous results reported from the Vietnamese provinces of HCMC, Thai Binh and Nha Trang (8.8, 1.8 and 3.2%, respectively) ([@bib43]). However, we were only able to establish the identity of the antimicrobial residue in 4 of 9 samples that tested positive by a bacterial inhibition test. This may be the result of a false-positive result in our screening test, or (more likely) due to the presence of antimicrobial residues not investigated in this study. All antimicrobials confirmed in our samples (tetracyclines, ciprofloxacin, flumequine) are known to be commonly used in Vietnamese aquaculture ([@bib32]), although levels of flumequine (two samples) and oxytetracycline (one sample) where within the legal limits. We found considerable agreement between the screening results by Charm II and the residues detected by LC-MS/MS. The exception was a macrolide-positive sample by Charm that subsequently tested negative for both erythromycin and tylosin. We hypothesize that this may reflect the use of spiramycin, another macrolide antimicrobial known to be used in aquaculture ([@bib37]) that was not investigated. It is likely that the observed prevalence of residues in shrimp samples reflects the use of antimicrobials late in the production cycle, thought to be common practice in Vietnamese aquaculture ([@bib32]). A surprising finding was the higher prevalence of residues in shrimps procured from supermarkets than from (more informal) street markets. This suggests that intensive production systems (normally associated with the supermarket supply chains) may be associated with a higher levels of antimicrobial usage. This is consistent with a previous study that reported a higher prevalence of residues in shrimp products procured in supermarkets compared with wholesale markets ([@bib43]). The observed prevalence of contamination with NTS in this study (75%), is higher than in previous studies from Vietnam, China, Thailand and Bangladesh (prevalence levels ranging between 13% and 55%) ([@bib25], [@bib33], [@bib34], [@bib44]). A recent study investigating NTS in 25 g meat samples purchased across markets in Vietnam resulted in a comparatively lower prevalence (71.8% in chicken, 70.7% in pork and 62.2% in beef samples) ([@bib28]). In contrast with the antimicrobial residue results, shrimp samples purchased in street markets had higher prevalence of NTS contamination than shrimps purchased in supermarkets, although this difference was not statistically significant. We hypothesize that this may reflect deficiencies in the cold chain associated with street markets. A study in Thailand reported absence of NTS in shrimps purchased in supermarkets, compared with a 50.2% prevalence among shrimps purchased in street markets ([@bib25]).

We found a considerable serovar diversity (25) of NTS in our samples, with serovars Braenderup, Anatum, Saintpaul and Rissen accounting for 46.7% of all NTS isolates. Most serovars detected in shrimps have been isolated in outbreaks of human disease in different countries. A study from 2004 on 56 human clinical (diarrhoea, fever) in Vietnam identified 12 different serovars ([@bib45]), of which four (Anatum, Albany, Typhimurium and Enteritidis) were detected in our shrimp samples. However, in that study, serovars Typhimurium and Enteritidis accounted for 50% of human cases, whereas in our study they only accounted for 6.6% of all isolates. A more recent study on invasive (bloodstream infection) isolates identified 19 serovars, of which 8 were identified in our study ([@bib19]). Surprisingly, serovar Weltevreden, which was predominant in a previous study on shrimp farms in the Mekong Delta of Vietnam ([@bib44]) was found only in one sample, and was a pansusceptible strain. A possible explanation for this discrepancy is that NTS contamination of shrimps mainly occurs after harvesting. It has been shown experimentally that seafood is an excellent nutrient media supporting vigorous post-harvest NTS multiplication at ambient temperatures ([@bib18]). Since no routine diagnostic or surveillance data exists for human salmonellosis, it is not possible to know to what extent shrimps are a significant source of NTS to the community in Vietnam. A total of 58.9% NTS isolates were MDR, a figure higher compared with overall MDR prevalence in isolates from meat in a previous study using the same antimicrobial panel (52.2%) ([@bib28]). Overall resistance to ciprofloxacin (33.3%) is of great concern, since this antimicrobial is often used to treat enteric infections. We found that 7.8% isolates were ESBL-producers and were fully resistant to at least one of the four 3rd-4th generation cephalosporins investigated. ESBL-producing NTS organisms were identified as belonging to serovars Braenderup (1), Infantis (3), and Give (3). These ESBL-producing isolates were MDR (including quinolone resistance), although were susceptible to carbapenems. The latter is the first choice drug in the treatment of ESBL-producing microorganisms ([@bib48]).

All (100%) retail shrimp samples were contaminated with *Vibrio* spp., being *V. parahaemolyticus* the most prevalent species (87.5% samples). Other *Vibrio* species were isolated in 10.0--60.0% samples. These levels of contamination are comparable with studies in northern Vietnam (99.5% prevalence) ([@bib40]) and Malaysia (100%) ([@bib21]), although higher than results from Turkey (67%) ([@bib26]), confirming that *Vibrio* spp. organisms are omnipresent in the shrimp farm aquatic environment ([@bib13]). In addition to *V. parahaemolyticus*, both *V. vulnificus* and *V. cholerae* non-O1 are also known to cause severe human disease ([@bib11]). We did not, however, find evidence of any of the two major virulence genes investigated (*tdh* and *trh*) in any of the 133 *Vibrio* spp. isolates. Previous research in Malaysia has shown a low prevalence of *tdh* (4%) and *trh* (12%) genes in non-clinical *V. parahaemolyticus* isolates ([@bib31]). In a study on 47 environmental isolates from India, only 4.2% and 2.1% harboured the *tdh* and *trh* genes, respectively ([@bib17]). However there was no evidence of these genes in isolates investigated in northern Vietnam ([@bib40]), Hong Kong ([@bib46]), or Sri Lanka ([@bib17]). In the late 1990s', *V. parahaemolyticus* was implicated in a large outbreak of enteric disease in central Vietnam, with 548 cases reported ([@bib42]). It was determined in further analyses that the prevailing serovar changed over time (O3:K6 in 1997, O4:K68 in 1998, O1:K25 in 1998--1999), and that 85% clinical isolates harboured either the *tdh* or *trh* genes ([@bib9]).

We found that 82.7% of *Vibrio* spp. isolates were resistant to ampicillin (100% for *V. parahaemolyticus* and *V. alginolyticus*)*.* This prevalence was comparable to published resistance levels among *V. parahaemolyticus* isolates from shrimps in northern Vietnam (87%) and Malaysia (82%) ([@bib21], [@bib40]). A total of 31.3% *V. parahaemolyticus* isolates were resistant to third generation cephalosporins and 28.1% were ESBL producers. In about half of those strains, the gene carried was *bla*~CTX-M1~. However, in another half the molecular basis for ESBL activity could not be established. Given that these genes are highly mobile, and are often inserted in plasmids and transposons, we hypothesize that *V. parahaemolyticus* may act as a reservoir of ESBL genes ([@bib7]). Interestingly we found an association between the presence of ESBL in NTS and *V. parahaemolyticus* isolated from the same sample.

The study confirmed the association between presence of antimicrobial residues and phenotypic resistance in NTS and *Vibrio* spp. in the same samples. This may be a reflection of AMR selection during the farming process, or may alternatively reflect post-harvesting contamination. The latter would be likely if the antimicrobial residue in the sample contributed to preferentially select for contamination with more resistant strains.

This study provides evidence of high levels of contamination with antimicrobial residues, NTS and *Vibrio* spp. among shrimps purchased in retail sites in HCMC. We found a high prevalence of MDR among NTS, with worryingly high levels of quinolone resistance. Although most *Vibrio* spp. isolates are unlikely to be pathogenic, the high carriage levels of ESBL in *V. parahaemolyticus* is of concern. We recommend authorities to enforce existing policies aiming at restricting inappropriate antimicrobial usage on shrimp farms, stepping up hygiene conditions during harvesting, transporting and retailing of shrimps, and to establish monitoring of antimicrobial residues, NTS and *Vibrio* spp. (focused on ESBL and virulence factors) in Vietnam. These findings should encourage the establishment of microbiological surveillance systems focused on health hazards in aquaculture food products, as well as strengthening laboratory capacity to enable comparisons between NTS and *Vibrio* spp. isolates from shrimps and human cases of disease.
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Table APanel of antimicrobial residues tested by LC-MS/MS.Table AWHO categoryAntimicrobial classAntimicrobialHighest priority-critically importantFluoroquinolonesEnrofloxacin, ciprofloxacin, norfloxacin, flumequineMacrolidesTylosin, erythromycinHighly importantTetracyclinesTetracycline, oxytetracycline, chlortetracyclineSulfonamidesSulfadiazine, sulfamethazine, sulfaquinoxaline, sulfamethoxazoleTable BSerovar identity of 62 NTS isolates investigated by MLST.Table BNo.SerogroupSerovarSequence type (ST)Number of isolates1BSaintpaul503BSaintpaul2722BDerby4043BParatyphi B4224BTyphimurium3625BAgona1316BStanley2917BUnknownUnknown18CBraenderup3116CBraenderup2239CRissen469610CBovismorbificans1499111CInfantis32112CLitchfield214313COhio329114CAlbany292115CBareilly203116CKentucky314117CPotsdam2039118DEnteritidis11419EAnatum64820EGive5161EGive831121ESenftenberg14122EWeltevreden365123ELondon155124OtherPoona1069125OtherKedougou1543226OtherUrbana5121Table C.1Phenotypic antimicrobial susceptibility results for 90 NTS isolates from shrimps, listed by antimicrobial class ranked by their importance according to the WHO classification. The figures correspond to the number of intermediate resistant, followed by the number of fully resistant isolates.Table C.1Class and antimicrobialGroup B (n = 21)AgonaDerbyParatyphi BSaintpaulStanleyTyphimuriumUnknownIntermediate resistant (%)Fully resistant (%)No. isolates1439121Samples (n = 30) (%)1 (3.3%)2 (6.7%)1 (3.3%)5 (16.7%)1 (3.3%)2 (6.7%)1 (3.3%)**Highest priority-critically important**Cephalosporins (3rd & 4th gen.) Cefepime0│00│00│00│00│00│00│00(0%)0(0%) Cefixime0│00│00│00│00│00│00│00(0%)0(0%) Cefotaxime0│00│00│00│00│00│00│00(0%)0(0%) Ceftazidime0│00│00│00│00│00│00│00(0%)0(0%) Ceftriazone0│00│00│00│00│00│00│00(0%)0(0%)Polyymyxins Colistin0│00│00│00│00│00│00│00(0%)0(0%)Quinolones Ciprofloxacin1│04│02│00│90│11│00│18(38.1%)11(52.4%) Levofloxacin1│04│00│03│61│00│00│19(42.9%)7(33.3%) Moxifloxacin0│00│00│00│61│00│00│11(4.8%)7(33.3%) Nalidixic Acid0│00│00│00│60│00│00│10 (0%)7(33.3%) Ofloxacin0│10│40│00│90│10│00│10 (0%)16(76.2%)**High priority-critically important**Aminoglycosides Amikacin0│00│00│00│00│00│00│00 (0%)0 (0%) Gentamicin0│00│00│00│60│00│00│10 (0%)7(33.3%) Tobramycin0│00│00│07│00│00│00│07(33.3%)0 (0%)Carbapenems and other penems Ertapenem0│00│00│00│00│00│00│00(0%)0(0%) Imipenem0│00│00│00│00│00│00│00(0%)0(0%) Meropenem0│00│00│00│00│00│00│00(0%)0(0%)Glycylcyclines Tigecycline0│00│00│03│00│00│00│03(14.3%)0(0%)Monobactams Aztreonam0│00│00│00│00│00│00│00 (0%)0 (0%)Penicillins Ampicillin0│10│40│00│90│10│00│10(0%)16(76.2%) Piperacillin0│10│40│00│90│10│00│10 (0%)16(76.2%) Ticarcillin0│10│40│00│90│10│01│01(4.8%)15(71.4%)**Highly important**Amphenicols Chloramphenicol0│00│40│00│90│00│00│10(0%)14(66.7%)Cephalosporins (1st and 2nd gen.) Cefalotin0│01│00│00│00│00│00│01(4.8%)0(0%) Cefoxitin0│00│00│00│00│00│00│00 (0%)0(0%) Cefuroxime0│00│00│03│00│00│00│03(14.3%)0(0%) Cefuroxime Axetil0│00│00│03│00│00│00│03(14.3%)0(0%)Tetracyclines Minocycline0│10│41│00│90│12│00│13(14.3%)16(76.2%) Tetracycline0│10│40│00│90│10│01│01 (4.8%)15(71.4%)**Other**Penicillin & *β*-lactamase inhibitor Amoxicillin/Clavulanic Acid0│00│00│01│00│00│00│01(4.8%)0(0%) Piperacillin/Tazobactam0│00│00│00│00│00│00│00(0%)0(0%)Folate pathway inhibitors Trimethoprim0│10│10│00│80│10│00│00(0%)11(52.4%)Folate pathway inhibitors/Sulfonamides Trimethoprim/Sulfamethoxazole0│10│10│00│90│10│00│10(0%)13(61.9%)Nitrofurantoins Nitrofurantoin0│00│00│00│00│00│00│00(0%)0(0%)ESBL (%)----------------0(0%)MDR (%)1(100%)4(100%)--9(100%)1(100%)--1(100%)--16(76.2%)Table C.2Table C.2Class and antimicrobialGroup C (n = 37)AlbanyBareillyBovismor-bificansBraenderupInfantisKentuckyLitchfieldOhioPotsdamRissenIntermediate resistant (%)Fully resistant (%)No. isolates11313313219Samples (n = 30) (%)1 (3.3%)1 (3.3%)1 (3.3%)6 (20%)1 (3.3%)1 (3.3%)3 (10%)1 (3.3%)1 (3.3%)3 (10%)**Highest priority-critically important**Cephalosporins (3rd & 4th gen.) Cefepime0│00│00│00│00│00│00│00│00│00│00(0%)0(0%) Cefixime0│00│00│00│10│30│00│00│00│00│00(0%)4(10.8%) Cefotaxime0│00│00│00│10│30│00│00│00│00│00(0%)4(10.8%) Ceftazidime0│00│00│00│00│00│00│00│00│00│00(0%)0(0%) Ceftriazone0│00│00│00│10│30│00│00│00│00│00(0%)4(10.8%)Polyymyxins Colistin0│00│00│00│00│00│00│00│00│00│00 (0%)0(0%)Quinolones Ciprofloxacin1│00│10│02│80│31│01│20│00│14│09(24.3%)15(40.5%) Levofloxacin1│01│00│010│03│00│02│10│00│13│120(54.1%)3(8.1%) Moxifloxacin0│00│00│01│00│00│01│10│00│10│02 (5.4%)2(5.4%) Nalidixic Acid0│10│00│00│20│30│00│10│00│10│00(0%)8(21.6%) Ofloxacin0│10│10│00│100│30│00│30│00│11│31(2.7%)22 (59.5%)**High priority-critically important**Aminoglycosides Amikacin0│00│00│00│00│00│00│00│00│00│00(0%)0 (0%) Gentamicin0│00│00│00│10│30│00│00│00│10│00(0%)5(13.5%) Tobramycin0│01│00│00│10│30│01│00│01│00│03(8.1%)4 (10.8%)Carbapenems and other penems Ertapenem0│00│00│00│00│00│00│00│00│00│00(0%)0(0%) Imipenem0│00│00│00│00│00│00│00│00│00│00(0%)0(0%) Meropenem0│00│00│00│00│00│00│00│00│00│00(0%)0(0%)Glycylcyclines Tigecycline0│00│00│00│00│00│00│00│00│00│00(0%)0 (0%)Monobactams Aztreonam0│00│00│00│10│30│00│00│00│00│00(0%)4 (10.8%)Penicillins Ampicillin0│10│10│00│10│30│00│30│00│10│90(0%)19(51.4%) Piperacillin0│10│10│00│10│30│00│30│00│10│90(0%)19(51.4%) Ticarcillin0│10│10│00│10│30│00│30│00│10│90(0%)19(51.4%)**Highly important**Amphenicols Chloramphenicol0│10│10│00│10│30│00│30│00│11│61(2.7%)16(43.2%)Cephalosporins (1st and 2nd gen.) Cefalotin0│00│00│00│10│30│00│00│00│00│00(0%)4(10.8%) Cefoxitin0│00│00│00│03│00│00│00│00│00│03(8.1%)0(0%) Cefuroxime0│00│00│00│10│30│00│00│00│02│02(5.4%)4(10.8%) Cefuroxime Axetil0│00│00│00│10│30│00│00│00│02│02(5.4%)4(10.8%)Tetracyclines Minocycline0│00│00│00│10│30│00│30│00│10│90(0%)17(45.9%) Tetracycline0│10│00│00│10│30│00│30│00│10│90(0%)18(48.6%)**Other**Penicillin & *β*-lactamase inhibitor Amoxicillin/Clavulanic Acid1│00│00│00│00│00│00│00│00│00│01(2.7%)0(0%) Piperacillin/Tazobactam0│00│00│00│00│00│00│00│00│00│00(0%)0(0%)Folate pathway inhibitors Trimethoprim0│10│00│00│30│00│00│30│00│00│90(0%)16(43.2%)Folate pathway inhibitors/Sulfonamides Trimethoprim/Sulfamethoxazole0│10│00│00│30│00│00│30│00│10│90(0%)17(45.9%)Nitrofurantoins Nitrofurantoin0│00│00│06│10│30│00│00│00│00│06(16.2%)4(10.8%)ESBL (%)------1 (7.7%)3 (100%)------------4(10.8%)MDR (%)1(100%)1 (100%)--1(7.7%)3(100%)--3(100%)--1(100%)9(100%)--19(51.4%)Table C.3Table C.3Class and antimicrobialGroup E (n = 21)AnatumGiveLondonSenftenbergWeltevredenIntermediate resistant (%)Fully resistant (%)No. isolates114132Samples (n = 30) (%)5 (16.7%)2 (6.7%)1 (3.3%)1 (3.3%)1 (3.3%)**Highest priority-critically important**Cephalosporins (3rd & 4th gen.) Cefepime0│00│00│00│00│00(0%)0 (0%) Cefixime0│00│30│00│00│00(0%)3(14.3%) Cefotaxime0│00│30│00│00│00(0%)3(14.3%) Ceftazidime0│00│30│00│00│00(0%)3(14.3%) Ceftriazone0│00│30│00│00│00(0%)3(14.3%)Polyymyxins Colistin0│00│00│00│00│00 (0%)0 (0%)Quinolones Ciprofloxacin2│00│40│00│00│02(9.5%)4 (19%) Levofloxacin0│00│40│00│00│00(0%)4 (19%) Moxifloxacin0│00│40│00│00│00(0%)4 (19%) Nalidixic Acid0│00│40│00│00│00(0%)4 (19%) Ofloxacin0│00│40│00│00│00(0%)4 (19%)**High priority-critically important**Aminoglycosides Amikacin0│00│00│00│00│00(0%)0 (0%) Gentamicin0│00│30│00│00│00(0%)3(14.3%) Tobramycin0│00│30│00│00│00(0%)3(14.3%)Carbapenems and other penems Ertapenem0│00│00│00│00│00(0%)0(0%) Imipenem0│00│00│00│00│00(0%)0(0%) Meropenem0│00│00│00│00│00(0%)0(0%)Glycylcyclines Tigecycline0│00│30│00│00│00(0%)3(14.3%)Monobactams Aztreonam0│00│30│00│00│00(0%)3(14.3%)Penicillins Ampicillin0│70│40│10│00│00(0%)12(57.1%) Piperacillin0│70│40│10│00│00(0%)12(57.1%) Ticarcillin0│70│40│10│00│00(0%)12(57.1%)**Highly important**Amphenicols Chloramphenicol0│30│40│10│00│00(0%)8(38.1%)Cephalosporins (1st and 2nd gen.) Cefalotin0│00│30│00│00│00 (0%)3(14.3%) Cefoxitin0│00│00│00│00│00 (0%)0(0%) Cefuroxime5│00│30│00│00│05(23.8%)3(14.3%) Cefuroxime Axetil11│00│30│00│00│011(52.4%)3(14.3%)Tetracyclines Minocycline3│30│40│10│00│03(14.3%)8(38.1%) Tetracycline0│100│40│10│00│00(0%)15(71.4%)**Other**Penicillin & *β*-lactamase inhibitor Amoxicillin/Clavulanic Acid0│00│00│00│00│00(0%)0(0%) Piperacillin/Tazobactam0│00│00│00│00│00(0%)0(0%)Folate pathway inhibitors Trimethoprim0│90│40│10│00│00(0%)14(66.7%)Folate pathway inhibitors/Sulfonamides Trimethoprim/Sulfamethoxazole0│30│40│10│00│00(0%)8(38.1%)Nitrofurantoins Nitrofurantoin0│00│00│00│00│00(0%)0 (0%)ESBL (%)3 (75%)--------3(14.3%)MDR (%)10(90.9%)4(100%)1(100%)------15(71.4%)Table C.4Table C.4Class and antimicrobialOther serogroups (N = 11)EnteritidisKedougouPoonaUrbanaIntermediate resistant (%)Fully resistant (%)No. isolates4232Samples (n = 30) (%)2 (6.7%)1 (3.3%)1 (3.3%)1 (3.3%)**Highest priority-critically important**Cephalosporins (3rd & 4th gen.) Cefepime0│00│00│00│00(0%)0(0%) Cefixime0│00│00│00│00(0%)0(0%) Cefotaxime0│00│00│00│00(0%)0(0%) Ceftazidime0│00│00│00│00(0%)0(0%) Ceftriazone0│00│00│00│00(0%)0(0%)Polyymyxins Colistin0│10│00│00│00(0%)1(9.1%)Quinolones Ciprofloxacin3│01│00│00│04(36.4%)0 (0%) Levofloxacin3│01│00│00│04(36.4%)0 (0%) Moxifloxacin0│00│00│00│00 (0%)0 (0%) Nalidixic Acid0│30│00│00│00 (0%)3 (27.3%) Ofloxacin3│00│10│00│03 (27.3%)1 (9.1%)**High priority-critically important**Aminoglycosides Amikacin0│00│00│00│00(0%)0(0%) Gentamicin0│00│00│00│00(0%)0(0%) Tobramycin0│00│00│00│00(0%)0(0%)Carbapenems and other penems Ertapenem0│00│00│00│00(0%)0(0%) Imipenem0│00│00│00│00(0%)0(0%) Meropenem0│00│00│00│00(0%)0(0%)Glycylcyclines Tigecycline0│00│00│00│00 (0%)0(0%)Monobactams Aztreonam0│00│00│00│00 (0%)0(0%)Penicillins Ampicillin0│30│00│00│00(0%)3(27.3%) Piperacillin0│30│00│00│00(0%)3(27.3%) Ticarcillin0│30│00│00│00(0%)3(27.3%)**Highly important**Amphenicols Chloramphenicol0│00│00│00│00(0%)0 (0%)Cephalosporins (1st and 2nd gen.) Cefalotin2│00│00│00│02(18.2%)0(0%) Cefoxitin0│00│00│00│00(0%)0(0%) Cefuroxime0│01│00│00│01 (9.1%)0(0%) Cefuroxime Axetil2│01│00│00│03(27.3%)0(0%)Tetracyclines Minocycline0│31│00│00│01(9.1%)3(27.3%) Tetracycline0│30│00│00│00(0%)3(27.3%)**Other**Penicillin & *β*-lactamase inhibitor Amoxicillin/Clavulanic Acid1│00│00│00│01(9.1%)0(0%) Piperacillin/Tazobactam0│00│00│00│00(0%)0(0%)Folate pathway inhibitors Trimethoprim0│00│00│00│00(0%)0(0%)Folate pathway inhibitors/Sulfonamides Trimethoprim/Sulfamethoxazole0│00│00│00│00(0%)0(0%)Nitrofurantoins Nitrofurantoin0│30│00│00│00(0%)3(27.3%)ESBL (%)----------0(0%)MDR (%)3(75%)--------3(27.3%)Table C.5Table C.5Class and antimicrobial Isolates (n = 90)All serovarsCLSI 2017 breakpointsNo. isolates (N = 90)Intermediate resistant (%)Fully resistant (%)SensitiveResistant**Highest priority-critically important**Cephalosporins (3rd & 4th gen.) Cefepime0│00(0%)0(0%)≤2≥16 Cefixime0│70(0%)7(7.8%)≤1≥4 Cefotaxime0│70(0%)7(7.8%)≤1≥4 Ceftazidime0│30(0%)3(3.3%)≤4≥16 Ceftriazone0│70(0%)7(7.8%)≤1≥4Polyymyxins Colistin0│10 (0%)1(1.1%)≤2\>2Quinolones Ciprofloxacin23│3023(25.6%)30(33.3%)≤0.06≥1 Levofloxacin33│1433(36.7%)14(15.6%)≤0.12≥2 Moxifloxacin3│133(3.3%)13(14.4%)≤2≥8 Nalidixic Acid0│220(0%)22(24.4%)≤16≥32 Ofloxacin4│434(4.4%)43(47.8%)≤0.12≥2**High priority-critically important**Aminoglycosides Amikacin0│00(0%)0(0%)≤16≥64 Gentamicin0│150(0%)15(16.7%)≤4≥16 Tobramycin10│710(11.1%)7(7.8%)≤4≥16Carbapenems and other penems Ertapenem0│00(0%)0(0%)≤0.5≥2 Imipenem0│00(0%)0(0%)≤1≥4 Meropenem0│00(0%)0(0%)≤1≥4Glycylcyclines Tigecycline3│33(3.3%)3(3.3%)≤2≥8Monobactams Aztreonam0│70(0%)7(7.8%)≤4≥16Penicillins Ampicillin0│500(0%)50(55.6%)≤8≥32 Piperacillin0│500(0%)50(55.6%)≤16≥128 Ticarcillin1│491(1.1%)49(54.4%)≤16≥128**Highly important**Amphenicols Chloramphenicol1│381 (1.1%)38 (42.2%)≤8≥32Cephalosporins (1st and 2nd gen.) Cefalotin3│73(3.3%)7(7.8%)≤8≥32 Cefoxitin3│03(3.3%)0 (0%)≤8≥32 Cefuroxime11│711(12.2%)7(7.8%)≤8≥32 Cefuroxime Axetil19│719(21.1%)7(7.8%)≤4≥32Tetracyclines Minocycline7│447(7.8%)44(48.9%)≤4≥16 Tetracycline1│511(1.1%)51(56.7%)≤4≥16**Other**Penicillin & *β*-lactamase inhibitor Amoxicillin/Clavulanic Acid3│03(3.3%)0(0%)≤8/4≥32/16 Piperacillin/Tazobactam0│00(0%)0(0%)≤16/4≥128/4Folate pathway inhibitors Trimethoprim0│410(0%)41(45.6%)≤8≥16Folate pathway inhibitors/Sulfonamides Trimethoprim/Sulfamethoxazole0│380(0%)38(42.2%)≤2/38≥4/76Nitrofurantoins Nitrofurantoin6│76(6.7%)7 (7.8%)≤32≥128ESBL (%)----7(7.8%)----MDR (%)----53(58.9%)----Table DPhenotypic antimicrobial susceptibility results for Vibrio spp. isolates (n = 133). The figures correspond to the number of intermediate resistant, followed by the number of fully resistant isolates.Table DClass and antimicrobialNo. isolates and percent resistant (%) (n = 133 isolates)DiskZone diameter (mm)*V. parahaemolyticus* (n = 64)*V. navarrensis* (n = 23)*V. alginolyticus* (n = 21)*V. cholerae* non-O1 (n = 15)*V. vulnificus* (n = 6)*V. fluvialis* (n = 4)Total intermediate resistant (%)Total fully resistant (%)antimicrobial(*μ*g/mL)SensitiveResistant**Highest priority-critically important***Cephalosporins (3*rd *&4*th *gen.)* Cefotaxime3ǀ2010ǀ20ǀ08ǀ02ǀ00ǀ023 (17.3%)22 (16.5%)30≥23≤14 Ceftazidime3ǀ100ǀ00ǀ01ǀ10ǀ00ǀ04 (3.0%)11 (8.3%)30≥18≤14*Quinolones* Ciprofloxacin9ǀ70ǀ01ǀ02ǀ01ǀ00ǀ013 (9.8%)7 (5.3%)5≥21≤15 Ofloxacin3ǀ60ǀ00ǀ02ǀ00ǀ00ǀ05 (3.8%)6 (4.5%)5≥16≤12**High priority-critically important***Aminoglycosides* Amikacin29ǀ11ǀ01ǀ00ǀ01ǀ00ǀ032 (24.0%)1 (0.8%)30≥17≤14 Gentamicin7ǀ01ǀ01ǀ00ǀ00ǀ00ǀ09 (6.8%)0 (0%)10≥15≤12*Carbapenems and other penems* Imipenem0ǀ20ǀ10ǀ01ǀ00ǀ00ǀ01 (0.8%)3 (2.3%)10≥16≤13*Penicillins* Ampicillin0ǀ646ǀ120ǀ213ǀ81ǀ20ǀ310 (7.5%)110 (82.7%)10≥17≤13 Amoxicillin-clavulanic acid1ǀ68ǀ40ǀ03ǀ52ǀ03ǀ017 (12.8%)15 (11.3%)20ǀ10≥18≤13**Highly important***Amphenicols* Chloramphenicol3ǀ11ǀ00ǀ01ǀ01ǀ00ǀ06 (4.5%)1 (0.8%)30≥18≤12*Tetracyclines* Tetracycline15ǀ73ǀ10ǀ01ǀ10ǀ10ǀ019 (14.3%)10 (7.5%)30≥19≤14*Folate pathway inhibitors & sulfonamides* Trimethoprim/sulfamethoxazole7ǀ173ǀ31ǀ00ǀ31ǀ21ǀ013 (9.8%)25 (18.8%)1.25/23.75≥16≤10**ESBL**1800000--18 (13.5%)**MDR**1800000--18 (13.5%)
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[^1]: VND=Vietnam Dong (1USD = 23 kVND).

[^2]: Highest priority, critically important antimicrobial; ND=Not detected; MRL = Maximum Residue Limits according to Vietnamese regulation.
